HAL (France)
open access
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era#677239
- Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors#1113951
- A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi#813784
- Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer#374393
- Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer#879117
Record · ID 374401
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive